Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immutep Ltd ( (AU:IMM) ) just unveiled an announcement.
Immutep Limited has announced significant progress in its global TACTI-004 (KEYNOTE-F91) Phase III trial, which is evaluating the combination of eftilagimod alfa (efti) and MSD’s KEYTRUDA® for advanced non-small cell lung cancer. The trial has enrolled 289 patients, with over 120 clinical sites activated across 27 countries, including the United States. This progress is bolstered by a recent licensing deal with Dr Reddy’s for emerging markets, and the company remains on track for key milestones, including a futility analysis in early 2026 and full patient enrolment by the third quarter of 2026.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the research and development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to leverage this expertise to provide innovative treatment options and maximize shareholder value.
YTD Price Performance: 2.74%
Average Trading Volume: 2,945,207
Technical Sentiment Signal: Buy
Current Market Cap: A$552.6M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.